SEARCH

SEARCH BY CITATION

References

  • 1
    EpleJN, SauterG, EpsteinJI, SesterhennIA, eds. Pathology and genetics: tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004. 359p.
  • 2
    Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982; 297: 4748.
  • 3
    Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001; 54: 21521.
  • 4
    Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF. Focus on bladder cancer. Cancer Cell 2004; 6: 1116.
  • 5
    Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23: 1820.
  • 6
    Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001; 20: 68691.
  • 7
    van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61: 12658.
  • 8
    Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004; 23: 162730.
  • 9
    Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ, Sauter G. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004; 23: 561623.
  • 10
    Guo Z, Linn JF, Wu G, Anzick SL, Eisenberger CF, Halachmi S, Cohen Y, Fomenkov A, Hoque MO, Okami K, Steiner G, Engles JM, et al. CDC91L1 is a newly discovered oncogene in human bladder cancer. Nat Med 2004; 10: 37481.
  • 11
    Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, de Kok JB. CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. Int J Cancer 2005; 116: 2824.
  • 12
    Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994; 54: 531538.
  • 13
    Hovey RM, Chu L, Balazs M, DeVries S, Moore D, Sauter G, Carroll PR, Waldman FM. Genetic alterations in primary bladder cancers and their metastases. Cancer Res 1998; 58: 355560.
  • 14
    Bruch J, Schulz WA, Melzner I, Kemmerling R, Brüderlein S, Möller P, Vogel W, Hameister H. Concurrent gain of chromosomes 5p, 6p, and 20q in bladder carcinoma cell lines: delineation of the 6p22 amplification unit. Cancer Res 2000; 60: 452630.
  • 15
    Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. BMC Mol Cancer 2005; 4: 16.
  • 16
    Florl AR, Franke KH, Niederacher D, Gerharz CD, Seifert HH, Schulz WA. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest 2000; 80: 151322.
  • 17
    Chapman EJ, Harnden P, Chambers P, Johnston C, Knowles MA. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 2005; 11: 57407.
  • 18
    Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J Urol 2003; 170: 6014.
  • 19
    Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003; 63: 76526.
  • 20
    Habuchi T, Takahashi T, Kakinuma H, Wang L, Tsuchiya N, Satoh S, Akao T, Sato K, Ogawa O, Knowles MA, Kato T. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 2001; 20: 5317.
  • 21
    Wright KO, Messing EM, Reeder JE. DBCCR1 mediates death in cultured bladder tumor cells. Oncogene 2004; 23: 8290.
  • 22
    Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004; 432: 32431.
  • 23
    Thievessen I, Wolter M, Prior A, Seifert HH, Schulz WA. Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines. J Cell Physiol 2005; 203: 3727.
  • 24
    Aboulkassim TO, LaRue H, Lemieux P, Rousseau F, Fradet Y. Alteration of the PATCHED locus in superficial bladder cancer. Oncogene 2003; 22: 296771.
  • 25
    Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, Carroll P, Kuo WL, Pinkel D, Albertson D, Cordon-Cardo C, Jian AN. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003; 63: 287280.
  • 26
    Primdahl H, Wikman FP, von der Maase H, Zhou XG, Wolf H, Orntoft TF. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 2002; 94: 21623.
  • 27
    Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003; 33: 906.
  • 28
    Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vögeli TA, Grimm MO. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 2004; 10: 341021.
  • 29
    Blaveri E, Simko J, Korkola JE, Brewer JL, Baehner F, Mehta K, deVries S, Koppie T, Pejavar S, Carroll P, Waldman FM. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005; 11: 404455.
  • 30
    Wild PJ, Herr A, Wissmann C, Stoehr R, Rosenthal A, Zaak D, Simon R, Knuechel R, Pilarsky C, Hartmann A. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005; 11: 441529.
  • 31
    Celis JE, Gromova I, Moreira JM, Cabezon T, Gromov P. Impact of proteomics on bladder cancer research. Pharmacogenomics 2004; 5: 38194.
  • 32
    Helpap B, Schmitz-Drager BJ, Hamilton PW, Muzzonigro G, Galosi AB, Kurth KH, Lubaroff D, Waters DJ, Droller MJ. Molecular pathology of non-invasive urothelial carcinomas. Virchows Arch 2003; 442: 30916.
  • 33
    Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 100713.
  • 34
    Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX. P53 as a prognostic marker for bladder cancer: a metaanalysis and review. Lancet Oncol 2005; 6: 678686.
  • 35
    Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 86470.
  • 36
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 37
    Shiina H, Igawa M, Shigeno K, Terashima M, Deguchi M, Yamanaka M, Ribeiro-Filho L, Kane CJ, Dahiya R. Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 genes in bladder cancer. J Urol 2002; 168: 22206.
  • 38
    Stoehr R, Krieg RC, Knuechel R, Hofstaedter R, Pilarsky C, Zaak D, Schmitt R, Hartmann A. No evidence for involvement of beta-catenin and APC in urothelial carcinomas. Int J Oncol 2002; 20: 90511.
  • 39
    Thievessen I, Seifert HH, Swiatkowski S, Florl AR, Schulz WA. E-cadherin involved in inactivation of WNT/β-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer 2003; 88: 19328.
  • 40
    Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004; 430: 797802.
  • 41
    Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002; 21: 247683.
  • 42
    Christoph F, Schmidt B, Schmitz-Dräger BJ, Schulz WA. Overexpression and amplification of the c-myc gene in human urothelial carcinoma. Int J Cancer 1999; 84: 16973.
  • 43
    Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitz-Dräger BJ. Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer 1998; 77: 51521.
  • 44
    Franke KH, Miklosi M, Goebell P, Clasen S, Steinhoff C, Anastasiadis AG, Gerharz CD, Schulz WA. Cyclin-dependent kinase inhibitor p27KIP1 is expressed preferentially in early stages of urothelial carcinoma. Urology 2000; 56: 68995.
  • 45
    Hoffmann MJ, Florl AR, Seifert HH, Schulz WA. Multiple mechanisms inactivating CDKN1C in bladder cancer. Int J Cancer 2005; 114: 40613.
  • 46
    Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin OK. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63: 810812.
  • 47
    Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005; 24: 521825.
  • 48
    Varley C, Hill G, Pellegrin S, Shaw NJ, Selby PJ, Trejdosiewicz LK, Southgate J. Autocrine regulation of human urothelial proliferation and migration during regenerative responses in vitro. Exp Cell Res 2005; 306: 21629.
  • 49
    Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F, Schulz WA. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 2003; 282: 4857.
  • 50
    Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 81322.
  • 51
    Deng Q, Liao R, Wu BL, Sun P. High intensity RAS signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem 2004; 279: 10509.
  • 52
    Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A, Wu XR. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001; 20: 197380.
  • 53
    Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999; 59: 35127.
  • 54
    Makri D, Schulz WA, Grimm MO, Clasen S, Bojar H, Schmitz-Dräger BJ. WAF1/p21 regulates proliferation but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. Int J Oncol 1998; 12: 6218.
  • 55
    Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, Hamdy FC. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005; 23: 290310.
  • 56
    Florl AR, Loewer R, Schmitz-Dräger BJ, Schulz WA. DNA methylation and expression of L1 LINE and HERV-K provirus sequences in urothelial and renal cell carcinoma. Br J Cancer 1999; 80: 131221.
  • 57
    Kimura F, Seifert HH, Florl AR, Santourlidis S, Steinhoff C, Swiatkowski S, Mahotka C, Gerharz CD, Schulz WA. Decreased DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma. Int J Cancer 2003; 104: 56878.
  • 58
    Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5: 71325.